Company Overview
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Woodstock, Georgia, with manufacturing operations in Jalisco, Mexico. European marketing and sales are headquartered in Roermond, Netherlands.

Management Team
Amy Trombly
Interim Chief Executive Officer
Bruce Thornton
Chief Operating Officer
Jerry Dvonch
Chief Financial Officer

Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022
Jan 5 2022, 4:55 PM EST

Sonoma Pharmaceuticals Reports Second Quarter FY 2022 Financial Results
Nov 15 2021, 8:00 AM EST

Sonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast Asia
Nov 9 2021, 7:00 AM EST

Stock Overview
Symbol: SNOA
Exchange: Nasdaq
Market Cap: 14.37m
Last Price: $4.64
52-Week: $4.2001 - $13.36

Investor Relations
T: 470-938-1011
ir@sonomapharma.com

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.